Cargando…

Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19

BACKGROUND: Disease severity in COVID-19 ranges from asymptomatic infection to severe disease and death, especially in older subjects. The risk for severe infection and death has been reported to be 2X in those between 30 and 40 years, 3X in those between 40 and 50 years, and 4X in those between 50...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Chunmei, Li, Qing, Li, Linhai, Peng, Xiaohua, Ling, Zhijian, Xiao, Bin, Feng, Jingjing, Chen, Zhenhong, Chang, De, Xie, Lixin, Dela Cruz, Charles S, Sharma, Lokesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020811/
https://www.ncbi.nlm.nih.gov/pubmed/33833543
http://dx.doi.org/10.2147/JIR.S304190
_version_ 1783674631609122816
author Xie, Chunmei
Li, Qing
Li, Linhai
Peng, Xiaohua
Ling, Zhijian
Xiao, Bin
Feng, Jingjing
Chen, Zhenhong
Chang, De
Xie, Lixin
Dela Cruz, Charles S
Sharma, Lokesh
author_facet Xie, Chunmei
Li, Qing
Li, Linhai
Peng, Xiaohua
Ling, Zhijian
Xiao, Bin
Feng, Jingjing
Chen, Zhenhong
Chang, De
Xie, Lixin
Dela Cruz, Charles S
Sharma, Lokesh
author_sort Xie, Chunmei
collection PubMed
description BACKGROUND: Disease severity in COVID-19 ranges from asymptomatic infection to severe disease and death, especially in older subjects. The risk for severe infection and death has been reported to be 2X in those between 30 and 40 years, 3X in those between 40 and 50 years, and 4X in those between 50 and 65 years, compared to the reference group of 18–29 years. OBJECTIVE: To investigate the early changes in host immune responses that are altered with age and the difference in the early host inflammatory response that dictates a symptomatic versus asymptomatic course of COVID-19. PATIENTS AND METHODS: COVID-19 subjects were identified by screening at the airport upon arrival from a foreign destination to China. Patients were either asymptomatic or had a mild disease when the first oro-pharyngeal (OP) swab samples were collected. Patients were quarantined and blood and throat swabs were collected during the course of the disease, allowing identification of the earliest host response to COVID-19. These patients were followed until their OP sample turned COVID-19 negative. RESULTS: Data were obtained from 126 PCR-confirmed COVID-19 patients. The blood samples were obtained within 48 days of qPCR confirmation of viral infection. Older subjects (>30 years) had significantly elevated levels of anti-inflammatory cytokine IL-10, a significant decrease in the percentage of CD8+ T cells, and expansion in NKT cell fraction. This was associated with significantly elevated viral load and a delayed humoral response in older subjects. Compared to symptomatic subjects, asymptomatic patients had an early increase in pro-inflammatory cytokine IL-2, while a decrease in both T regulatory cells and anti-inflammatory cytokine IL-10. Further, asymptomatic disease was associated with early humoral response and faster viral clearance. CONCLUSION: Early inflammatory response potentially plays a critical role for host-defense in COVID-19. The impaired early inflammatory response was associated with older age while a robust early inflammation was associated with asymptomatic disease.
format Online
Article
Text
id pubmed-8020811
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-80208112021-04-07 Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19 Xie, Chunmei Li, Qing Li, Linhai Peng, Xiaohua Ling, Zhijian Xiao, Bin Feng, Jingjing Chen, Zhenhong Chang, De Xie, Lixin Dela Cruz, Charles S Sharma, Lokesh J Inflamm Res Original Research BACKGROUND: Disease severity in COVID-19 ranges from asymptomatic infection to severe disease and death, especially in older subjects. The risk for severe infection and death has been reported to be 2X in those between 30 and 40 years, 3X in those between 40 and 50 years, and 4X in those between 50 and 65 years, compared to the reference group of 18–29 years. OBJECTIVE: To investigate the early changes in host immune responses that are altered with age and the difference in the early host inflammatory response that dictates a symptomatic versus asymptomatic course of COVID-19. PATIENTS AND METHODS: COVID-19 subjects were identified by screening at the airport upon arrival from a foreign destination to China. Patients were either asymptomatic or had a mild disease when the first oro-pharyngeal (OP) swab samples were collected. Patients were quarantined and blood and throat swabs were collected during the course of the disease, allowing identification of the earliest host response to COVID-19. These patients were followed until their OP sample turned COVID-19 negative. RESULTS: Data were obtained from 126 PCR-confirmed COVID-19 patients. The blood samples were obtained within 48 days of qPCR confirmation of viral infection. Older subjects (>30 years) had significantly elevated levels of anti-inflammatory cytokine IL-10, a significant decrease in the percentage of CD8+ T cells, and expansion in NKT cell fraction. This was associated with significantly elevated viral load and a delayed humoral response in older subjects. Compared to symptomatic subjects, asymptomatic patients had an early increase in pro-inflammatory cytokine IL-2, while a decrease in both T regulatory cells and anti-inflammatory cytokine IL-10. Further, asymptomatic disease was associated with early humoral response and faster viral clearance. CONCLUSION: Early inflammatory response potentially plays a critical role for host-defense in COVID-19. The impaired early inflammatory response was associated with older age while a robust early inflammation was associated with asymptomatic disease. Dove 2021-03-30 /pmc/articles/PMC8020811/ /pubmed/33833543 http://dx.doi.org/10.2147/JIR.S304190 Text en © 2021 Xie et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Xie, Chunmei
Li, Qing
Li, Linhai
Peng, Xiaohua
Ling, Zhijian
Xiao, Bin
Feng, Jingjing
Chen, Zhenhong
Chang, De
Xie, Lixin
Dela Cruz, Charles S
Sharma, Lokesh
Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19
title Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19
title_full Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19
title_fullStr Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19
title_full_unstemmed Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19
title_short Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19
title_sort association of early inflammation with age and asymptomatic disease in covid-19
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020811/
https://www.ncbi.nlm.nih.gov/pubmed/33833543
http://dx.doi.org/10.2147/JIR.S304190
work_keys_str_mv AT xiechunmei associationofearlyinflammationwithageandasymptomaticdiseaseincovid19
AT liqing associationofearlyinflammationwithageandasymptomaticdiseaseincovid19
AT lilinhai associationofearlyinflammationwithageandasymptomaticdiseaseincovid19
AT pengxiaohua associationofearlyinflammationwithageandasymptomaticdiseaseincovid19
AT lingzhijian associationofearlyinflammationwithageandasymptomaticdiseaseincovid19
AT xiaobin associationofearlyinflammationwithageandasymptomaticdiseaseincovid19
AT fengjingjing associationofearlyinflammationwithageandasymptomaticdiseaseincovid19
AT chenzhenhong associationofearlyinflammationwithageandasymptomaticdiseaseincovid19
AT changde associationofearlyinflammationwithageandasymptomaticdiseaseincovid19
AT xielixin associationofearlyinflammationwithageandasymptomaticdiseaseincovid19
AT delacruzcharless associationofearlyinflammationwithageandasymptomaticdiseaseincovid19
AT sharmalokesh associationofearlyinflammationwithageandasymptomaticdiseaseincovid19